Keywords: Quantitative Imaging, Quantitative Imaging
Motivation: Regorafenib’s limited duration and resistance in CRC treatment necessitate strategies for enhanced efficacy.
Goal(s): To evaluate whether alternating regorafenib with imatinib can improve therapeutic outcomes in CRC.
Approach: This study used mpMRI to monitor tumor microenvironment changes in CRC models receiving alternating regorafenib/imatinib, focusing on perfusion, hypoxia, and cellular responses.
Results: Alternating therapy achieved superior tumor perfusion, sustained hypoxia reduction, and enhanced apoptosis, suggesting potential for improved patient survival and quality of life.
Impact: This study demonstrates that alternating regorafenib and imatinib therapy enhances tumor response, prolongs antitumor effects, and overcomes treatment resistance, improving survival outcomes in CRC.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords